Pancreatic Cancer Research

ResearcherTexas A&M UniversityActive in the last 2 years

Maen Abdelrahim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6631-5035; OpenAlex author ID A5088223962, A5110723536. Sources: OpenAlex.

Their work

Papers
20 (first author 2, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
44
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 4 papers · 2021: 3 papers · 2022: none · 2023: none · 2024: 3 papers · 2025: 3 papers · 2026: 4 papers

Papers 20

  1. Neoadjuvant Therapy and Pancreatic Cancer Resection Outcomes: A Retrospective Analysis at a Quaternary Care Center. Co-author DOI 10.1016/j.jss.2026.02.012↗
  2. Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial. Co-author DOI 10.1080/14796694.2026.2664776↗
  3. NALIRIFOX versus FOLFIRINOX: reconstructed individual patient data meta-analysis of efficacy and safety in first-line treatment of unresectable or metastatic p… Last author DOI 10.3389/fonc.2026.1902839↗
  4. Prognostic Impact of Baseline Circulating Tumor DNA (ctDNA) in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. Co-author DOI 10.3390/cancers18142286↗
  5. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  6. Correlative Analysis of Tumor-Informed Circulating Tumor DNA (ctDNA) and the Survival Outcomes of Patients with Pancreatic Adenocarcinoma. Last author DOI 10.3390/biomedicines13051124↗
  7. An 81-Year-Old Geriatric Patient with Metastatic Pancreatic Cancer Demonstrating Excellent Response and Well Tolerance to NALIRIFOX: A Case Report and Literatu… Last author DOI 10.3390/reports8020069↗
  8. Comparative molecular profiling of pancreatic ductal adenocarcinoma of the head versus body and tail. Co-author DOI 10.1038/s41698-024-00571-4↗
  9. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. First author DOI 10.1093/oncolo/oyae155↗
  10. Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments. Last author DOI 10.3389/fonc.2024.1386699↗
  11. Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan. Co-author DOI 10.3389/fonc.2021.678070↗
  12. The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies. First author DOI 10.3390/biomedicines9040389↗
  13. Transcription factors specificity protein and nuclear receptor 4A1 in pancreatic cancer. Last author DOI 10.3748/wjg.v27.i38.6387↗
  14. Is Surgery-first Still a Reasonable Option in the Era of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer? Co-author DOI 10.1097/coc.0000000000000661↗
  15. Commentary on Neoadjuvant Versus Surgery First Approach in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/coc.0000000000000743↗
  16. Acquired haemophilia as a paraneoplastic manifestation of pancreatic cancer. Last author DOI 10.3332/ecancer.2020.1053↗
  17. Pancreatic adenocarcinoma with early esophageal metastasis: A case report and review of literature. Last author DOI 10.5306/wjco.v11.i2.83↗
  18. Promising new treatments for pancreatic cancer in the era of targeted and immune therapies. Co-author PMID 31598392↗
  19. Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) tra… Co-author DOI 10.1074/jbc.m114.592576↗
  20. Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors. Co-author DOI 10.1093/carcin/bgt231↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Abdullah Esmail · 7 shared papers, 2024–2026 · strength 1.78
  2. Bayan Khasawneh · 3 shared papers, 2025–2026 · strength 0.90
  3. Ashish Saharia · 4 shared papers, 2019–2026 · strength 0.59
  4. Kirk Heyne · 4 shared papers, 2019–2026 · strength 0.59
  5. Nestor F. Esnaola · 2 shared papers, 2024–2026 · strength 0.47
  6. Ahmed Elaileh · 3 shared papers, 2019–2026 · strength 0.45
  7. Farshid Dayyani · 2 shared papers, 2024–2026 · strength 0.43
  8. Gazala Naaz Khan · 2 shared papers, 2021–2026 · strength 0.40
  9. Anup Kasi · 2 shared papers, 2024 · strength 0.39
  10. Asem H. Mansour · 1 shared paper, 2026 · strength 0.29
  11. Hikmat Abdel‐Razeq · 1 shared paper, 2026 · strength 0.29
  12. Marwa Elsayed · 1 shared paper, 2021 · strength 0.28
  13. Ethan Alexander Burns · 2 shared papers, 2020–2021 · strength 0.28
  14. Zev A. Wainberg · 1 shared paper, 2026 · strength 0.28
  15. Andrea J. Bullock · 1 shared paper, 2026 · strength 0.28
  16. Hassan A. Hatoum · 1 shared paper, 2026 · strength 0.28
  17. Eileen Mary O'Reilly · 1 shared paper, 2026 · strength 0.28
  18. Yuqi Zhang · 1 shared paper, 2025 · strength 0.27
  19. Stephen H Safe · 3 shared papers, 2013–2021 · strength 0.24
  20. Benjamin Adam Weinberg · 1 shared paper, 2024 · strength 0.24
  21. Kelvin Allenson · 1 shared paper, 2026 · strength 0.23
  22. Ahmed Osama Gaber · 1 shared paper, 2026 · strength 0.23
  23. Ashton Anthony Connor · 1 shared paper, 2026 · strength 0.23
  24. Youssef E. Dib · 1 shared paper, 2026 · strength 0.23
  25. Doaa Bugazia · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.